What Is VIOO? Vanguard S&P Small-Cap 600 Index Fund ETF Shares

S&P will not add a company to the SmallCap 600 unless it has demonstrated positive earnings, both over the most recent four quarters combined and in the most recent quarter alone. Russell applies no such test to the 2000, admitting companies purely on size and liquidity. The consequence is that a meaningful share of the Russell 2000 consists of businesses that have never made money, while the 600 does not.

This is the most consequential distinction in US small-cap indexing, and it is one of the few index design choices with a clear mechanical rationale rather than a marketing one. It does not guarantee anything about performance. What it does is change the composition of the pool: fewer pre-revenue biotechnology companies, fewer speculative technology listings, more established smaller businesses.

The screen is not a permanent quality guarantee either. A company that qualifies on entry can subsequently lose money and remain in the index, since the test applies at admission rather than continuously. So the 600 is better described as filtered on the way in than as a portfolio of consistently profitable companies.

FormFactor and Viasat lead at 0.7% each, followed by Molina Healthcare, Argan, BrightSpring Health Services, Element Solutions and MaxLinear. The ten largest together come to 5.9% of assets, so this is about as evenly distributed as an equity fund gets. Individual company outcomes barely register at the fund level.

The overlap with growth-oriented small-cap funds is the more interesting observation. Argan, BrightSpring, MaxLinear, Krystal Biotech and ESCO Technologies each appear near the top of both this blend fund and a Russell 2000 growth fund. The small-cap universe is large in count but narrow at the top, and the companies that have grown enough to lead their index tend to lead several of them at once. Investors holding two small-cap funds for diversification often own more of the same names than they expect.

Sector weights are unusually balanced: financials 17%, technology 16%, industrials 16%, consumer discretionary 13% and healthcare 12%. No single sector dominates, which is a marked contrast with small-cap growth funds where healthcare can approach thirty percent, and with small-cap value funds where financials do the same.

At 0.07% VIOO is among the least expensive routes to the S&P 600 available, and cheaper than most style-split small-cap products by a wide margin. Because small-cap funds carry higher internal trading costs than large-cap ones, keeping the visible fee this low is more valuable here than the headline number suggests.

The 1.10% yield is unremarkable and appropriate. Smaller companies reinvest a larger share of earnings, and the index applies no dividend screen. Nobody should hold this for income.

It works as a complete small-cap allocation for an investor who wants the segment with the profitability filter applied and does not want to choose between value and growth. It is a poor fit for anyone specifically seeking exposure to the unprofitable, high-expectation end of the small-cap market, since the index rules exclude much of it by design. It is also redundant alongside a total US market fund, which already contains these companies at their market weight.

Approximate weights as of August 2026. Each ticker links to its individual stock guide in Walnut.

There are three common ways to get VIOO exposure. Buy shares (or fractional shares) of VIOO directly at any major broker that lists it. Hold it as a core position and layer more concentrated ideas on top. Or build it into a thematic portfolio in Walnut, so VIOO sits alongside other holdings that express the same thesis, with target weights you can rebalance toward. VIOO trades like a stock during market hours, so you buy it the same way you would any listed share.

New to buying funds? See how to buy an ETF, step by step.

Whether VIOO is a good buy depends less on any single call and more on your time horizon and what you already hold: it tracks the S&P SmallCap 600 Index, so the real question is whether you want that exposure in your mix and at what weight. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is VIOO a buy?

VIOO gives you the S&P SmallCap 600 Index exposure in one ticker at a 0.07% expense ratio. Most investors use it as a core holding and layer more concentrated thematic portfolios on top.

Whether VIOO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is VIOO a buy?

VIOO yields 1.10% as of August 2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see VIOO dividend: yield and schedule.

New to funds like VIOO? Start with what an ETF is, then how to buy an ETF, or browse the full guide to ETF investing.